跳至主要内容
临床试验/JPRN-jRCT2080222812
JPRN-jRCT2080222812未知1 期

A Phase I Study in Resminostat monotherapy and S-1/Resminostat therapy in Patients with biliary tract or pancreatic cancer

Yakult Honsha Co., Ltd.0 个研究点目标入组 44 人开始时间: 2015年4月6日最近更新:

试验速览

阶段
1 期
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 79age old(—)
性别
All

入选标准

  • (1)Patients with unresectable/recurrence biliary tract cancer (intrahepatic cholangiocarcinoma, extrahepatic bile duct carcinoma, gallbladder carcinoma and ampulla of Vater carcinoma) or unresectable/recurrence pancreatic cancer
  • (2)Patients who have received more than one regimen systemic chemotherapy history for biliary tract cancer or pancreatic cancer
  • (3)Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • (4)Patients who are able to ingest resminostat orally and have no gastrointestinal disturbance that, in the judgment of the investigator, may affect the absorption of resminostat

排除标准

  • (1)Patients who have taken HDAC inhibitor
  • (2)Pregnant women or lactating mothers
  • (3)Patients with brain metastases or suspected brain metastases based on the clinical symptoms

研究者

相似试验